2024-08-02 Deciphering Guidelines: Targeted Therapies for HR+/HER2- Early Breast Cancer Education Alert Breaking Down the Guidelines for HR-Positive/HER2-Negative Early Breast Cancer: An International Discussion on Who Could Benefit From Targeted Therapies 0.50 CME / ABIM MOC Are you aware of the clinical and pathological features that identify patients with a greater risk for breast cancer recurrence? Learn Now 92.52% of Pharmacists like you who have participated in similar programs believed the program would impact patient outcomes. 回上一頁
